Aprela, a single tablet formulation of bazedoxifene and conjugated equine estrogens (Premarin) for the potential treatment of menopausal symptoms

Current Opinion in Investigational Drugs

Volumn 11, Issue 4, 2010, Pages 464-471

  Stovall, Dale W ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRELA; BAZEDOXIFENE; BAZEDOXIFENE PLUS CONJUGATED ESTROGEN; CONJUGATED ESTROGEN; ESTRADIOL; ETHINYLESTRADIOL; LASOFOXIFENE; PLACEBO; RALOXIFENE; UNCLASSIFIED DRUG;

AMENORRHEA; BONE DENSITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; DYSPAREUNIA; ENDOMETRIUM HYPERPLASIA; HOT FLUSH; HUMAN; LUNG EMBOLISM; MENOPAUSAL SYNDROME; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE DRUG DOSE; TREATMENT RESPONSE; VAGINA ATROPHY; VAGINA BLEEDING; VAGINAL DRYNESS;

CLINICAL TRIALS, PHASE III AS TOPIC; ESTROGEN RECEPTOR ALPHA; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INDOLES; MENOPAUSE; RISK; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TABLETS;

EID: 77950112868     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Estrogen receptor ligands modulate its interaction with DNA. Cheskis BJ, Karathanasis S, Lyttle CR J BIOL CHEM 1997 272 17 11384-11391
2. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Fisher B, Constantino JP, Wickerman DL, Redmond CK, Kavanagh M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M et al J NATL CANCER INST 1998 90 18 1371-1388
3. Design, synthesis and preclinical characterization of novel, highly selective indole estrogens. Miller CP, Collini MD, Tran BD, Harris HA, Kharode YP, Marzolf JT, Moran RA, Henderson RA, Bender RHW, Unwalla RJ, Greenberger LM et al J MED CHEM 2001 44 11 1654-1657
4. Risks and benefits of estrogen plus progestin in healthy menopausal women: Principal results From the Women's Health Initiative randomized controlled trial. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SAA, Howard BV, Johnson KC, Kotchen M et al JAMA-J AM MED ASSOC 2002 288 3 321-333.
5. Developing a SERM: Stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Komm BS, Lyttle CR ANN NY ACAD SCI 2001 949 317-326.
6. Bazedoxifene + conjugated estrogens: A balanced combination to provide optimal "estrogenic" safety and efficacy. Komm BS, Kharode Y, Bodine P, Bex F AM SOC BONE MINER RES 2003 25 Abs SU385
7. Combining a SERM with conjugated estrogens (CE) to improve the SERM profile: Not all SERMs may succeed. Komm BS, Kharode Y, Bodine P, Bex F AM SOC BONE MINER RES 2003 25 Abs SU386
8. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA ENDOCRINOLOGY 1997 138 3 863-870
9. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC et al JAMA-J AM MED ASSOC 1999 282 7 637-645
10. Tibolone and low-dose continuous combined hormone treatment: Vaginal bleeding pattern, efficacy and tolerability. Hammar ML, Van De Weijer P, Franke HR, Pornel B, von Mauw EMJ, Nijland EA BJOG: INT J OBSTET GYNAECOL 2007 114 12 1522-1529
11. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Lobo RA, Pinkerton JV, Gass MLS, Dorin MH, Ronkin S, Pickar JH, Constantine G FERTIL STERIL 2009 92 3 1025-1038
12. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Pickar JH, Yeh IT, Bachmann G, Speroff L FERTIL STERIL 2009 92 3 1018-1024
13. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G FERTIL STERIL 2009 92 3 1045-1052
14. Differential biochemical and cellular actions of Premarin estrogens: Distinct pharmacology of bazedoxifene-conjugated estrogens combination. Berrodin TJ, Chang KCN, Komm BS, Freedman LP, Nagpal S MOL ENDOCRINOL 2009 23 1 74-85
15. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar JH MATURITAS 2009 63 4 329-335
16. Bazedoxifene/conjugated estrogens (BZA/CE): Incidence of uterine bleeding in postmenopausal women. Archer DE, Lewis V, Carr BR, Olivier S, Pickar JH FERTIL STERIL 2009 92 3 1039-1044
17. Pfizer and Wyeth become one: Working together for a healthier world. Pfizer Inc Press Release 2009 October 16
18. Relief of vasomotor symptoms with the tissueselective estrogen complex containing bazedoxifene/conjugated estrogens: A randomized, controlled trial. Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH MENOPAUSE 2009 16 6 1116-1124
19. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Bachmann G, Bobula J, Mirkin S Climacteric 2009 doi doi: 10.3109/13697130903305627
20. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, Robinson V, Henry D, O'Connell D, Cranney A ENDOCR REV 2002 23 4 529-539
21. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Maclennan AH, Broadbent JL, Lester S, Moore V COCHRANE DATABASE SYST REV 2004 4 CD002978
22. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: Results from the Women's Health Initiative randomized trial. Jackson RD, Wactawski-Wende J, LaCroix AZ, Pettinoer M, Yood RA, Watts NB, Robbins JA, Lewis CE, Beresford SAA, Ko MG, Naughton MJ et al J BONE MINER RES 2006 21 6 817-828
23. Association of exogenous estrogen and endometrial carcinoma. Smith DC, Prentice R, Thompson DJ, Hermann WL N ENGL J MED 1975 293 23 1164-1167
24. Effects of long-term estrogen replacement therapy. II. Neoplasia. Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT AM J OBSTET GYNECOL 1979 133 5 525-536
25. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: Two-year substudy results. Pickar JH, Yeh IT, Wheeler JE, Cunnane MF, Speroff L FERTIL STERIL 2003 80 5 1234-1240
26. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: The Women's Health Initiative randomized trial. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SAA, Pettinger M, Liu J, McNeeley SG, Lopez AM JAMA-J AM MED ASSOC 2003 290 13 1739-1748
27. Compliance with hormone replacement therapy in Thai women. Manonai J, Theppisai U, Suchartwatnachai C, Jetsawangsri T, Chittacharoen A MATURITAS 2003 44 3 201-205
28. Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. Guay MP, Dragomir A, Pilon D, Moride Y, Perreault S PHARMACOEPIDEMIOLOGY DRUG SAFETY 2007 16 1 17-27
29. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Kharode Y, Bodine PVN, Miller CP, Lyttle CR, Komm BS ENDOCRINOLOGY 2008 149 12 6084-6091
30. Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. Hanstein B, Djahansouzi S, Dall P, Beckmann MW, Bender HG EUR J ENDOCRINOL 2004 150 3 243-255
31. Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland. Crabtree JS, Peano BJ, Zhang XC, Komm AS, Winneker RC, Harris HA MOL CELL ENDOCRINOL 2008 287 1-2 40-46
32. Bazedoxifene combined with conjugated estrogens: A novel alternative to traditional hormone therapies. Van Duren D, Ronkin S, Pickar J, Constantine G FERTIL STERIL 2006 86 S88-S89
33. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, doubleblind, placebo-, and active-controlled study. Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD J BONE MINER RES 2008 23 4 525-535
34. Website pipeline: Pfizer. Pfizer Inc COMPANY WORLD WIDE WEB SITE 2010 January 27
35. Annual estimates of the population by sex and five-year age groups for the United States: April 1, 2000 to July 1, 2007 (NC-EST2007-01). US Census Bureau INTERNET SITE 2008 May 01
36. Menopausal symptoms and ethnicity: The study of women's health across the nation. Green R, Santoro N WOMENS HEALTH (LOND ENGL) 2009 5 2 127-133
37. Evolving issues in the clinical and managed care settings on the management of menopause following the Women's Health Initiative. Lukes A J MANAGE CARE PHARM 2008 14 3 Suppl 7-13
38. Estrogen agonists/antagonists in combination with estrogen for prevention and treatment of menopause-associated signs and symptoms. Stovall DW, Pinkerton JAV WOMENS HEALTH (LOND ENGL) 2008 4 3 257-268
39. Molecular mechanisms of estrogen action: Selective ligands and receptor pharmacology. Katzenellenbogen BS, Choi IH, Delage-Mourroux R, Ediger TR, Martini PGV, Montano M, Sun J, Weis K, Katzenellenbogen JA J STEROID BIOCHEM MOL BIOL 2000 74 5 279-285
40. Estrogens and menopause: Pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's. Bhavnani BR J STEROID BIOCHEM MOL BIOL 2003 85 2-5 473-482
41. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH MENOPAUSE 2009 doi: 10.1097/GME.0b013e3181b7c65f